Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Gains from Investment Securities (2016 - 2026)

Neurocrine Biosciences filings provide 15 years of Gains from Investment Securities readings, the most recent being -$3.4 million for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to -$3.4 million in Q3 2025 year-over-year; TTM through Dec 2025 was $259.2 million, a 43.85% decrease, with the full-year FY2024 number at $271.6 million, up 35.26% from a year prior.
  • Gains from Investment Securities hit -$3.4 million in Q3 2025 for Neurocrine Biosciences, down from $262.6 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $262.6 million in Q4 2024 to a low of -$3.4 million in Q3 2025.
  • Median Gains from Investment Securities over the past 4 years was $10.8 million (2021), compared with a mean of $80.3 million.
  • Biggest five-year swings in Gains from Investment Securities: crashed 85.94% in 2021 and later skyrocketed 31.96% in 2024.
  • Neurocrine Biosciences' Gains from Investment Securities stood at $1.8 million in 2021, then surged by 10955.56% to $199.0 million in 2023, then skyrocketed by 31.96% to $262.6 million in 2024, then plummeted by 101.29% to -$3.4 million in 2025.
  • The last three reported values for Gains from Investment Securities were -$3.4 million (Q3 2025), $262.6 million (Q4 2024), and $199.0 million (Q4 2023) per Business Quant data.